VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints

This article was originally published here

The Phase 3 study, which enrolled 2,838 adults, age 18-45 years, met both the primary and secondary endpoints. “We are thrilled with the results of the CONSTANT study,

The post VBI Vaccines announces second pivotal phase 3 study of Sci-B-Vac meets primary and secondary endpoints appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply